Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announces a business update and outlook for the development of its lead product ...
As previously announced Mendus AB (publ) (“Mendus”) has carried out a capital raise whereby 472,953,859 new shares were issued in a rights issue and 187,500,000 new shares were issued in a directed ...
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and ...
Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces positive 2-year follow-up data from the ALISON Phase 1 trial. The data ...
In the first quarter of 2025, Mendus provided a summary of the supportive feedback from EMA and FDA related to the preparations for a registration trial with our lead product vididencel in AML. The ...
ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemia Registration trial preparations are ongoing, following positive initial FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results